PMID- 37635994
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230829
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Electronic)
IS  - 2296-4185 (Linking)
VI  - 11
DP  - 2023
TI  - BMP-2 releasing mineral-coated microparticle-integrated hydrogel system for 
      enhanced bone regeneration.
PG  - 1217335
LID - 10.3389/fbioe.2023.1217335 [doi]
LID - 1217335
AB  - Introduction: Large bone defects (LBD) caused by trauma, infection, and tumor 
      resection remain a significant clinical challenge. Although therapeutic agents 
      such as bone morphogenetic protein-2 (BMP-2), have shown substantial potency in 
      various clinical scenarios, their uncontrollable release kinetics has raised 
      considerable concern from the clinical viewpoint. Mineral-coated microparticle 
      (MCM) has shown its excellent biologics loading and delivery potential due to its 
      superior protein-binding capacity and controllable degradation behaviors; thus, 
      it is conceivable that MCM can be combined with hydrogel systems to enable 
      optimized BMP-2 delivery for LBD healing. Methods: Herein, BMP-2 was immobilized 
      on MCMs via electrostatic interaction between its side chains with the coating 
      surface. Subsequently, MCM@BMP-2 is anchored into a hydrogel by the crosslinking 
      of chitosan (CS) and polyethylene glycol (PEG). Results and Discussion: This 
      microparticle-hydrogel system exhibits good biocompatibility, excellent 
      vascularization, and the sustained release of BMP-2 in the bone defect. 
      Furthermore, it is observed that this microsphere-hydrogel system accelerates 
      bone formation by promoting the expression of osteogenesis-related proteins such 
      as RUNX2, osteopontin, and osteocalcin in bone marrow mesenchymal stem cells 
      (BMSCs). Thus, this newly developed multifunctional microparticle-hydrogel system 
      with vascularization, osteogenesis, and sustained release of growth factor 
      demonstrates an effective therapeutic strategy toward LBD.
CI  - Copyright (c) 2023 Xu, Luo, Chen, Chen, Yu and Ye.
FAU - Xu, Hongwei
AU  - Xu H
AD  - Orthopaedic Oncology Services, Department of Orthopaedics, The Second Affiliated 
      Hospital of Zhejiang University School of Medicine, Hangzhou, China.
AD  - Jiaxing Key Laboratory of Basic Research and Clinical Translation on Orthopedic 
      Biomaterials, Department of Orthopaedics, The Second Affiliated Hospital of 
      Jiaxing University, Jiaxing, China.
FAU - Luo, Huanhuan
AU  - Luo H
AD  - Jiaxing Key Laboratory of Basic Research and Clinical Translation on Orthopedic 
      Biomaterials, Department of Orthopaedics, The Second Affiliated Hospital of 
      Jiaxing University, Jiaxing, China.
FAU - Chen, Jiayu
AU  - Chen J
AD  - Orthopaedic Oncology Services, Department of Orthopaedics, The Second Affiliated 
      Hospital of Zhejiang University School of Medicine, Hangzhou, China.
FAU - Chen, Gang
AU  - Chen G
AD  - Jiaxing Key Laboratory of Basic Research and Clinical Translation on Orthopedic 
      Biomaterials, Department of Orthopaedics, The Second Affiliated Hospital of 
      Jiaxing University, Jiaxing, China.
FAU - Yu, Xiaohua
AU  - Yu X
AD  - Orthopaedic Oncology Services, Department of Orthopaedics, The Second Affiliated 
      Hospital of Zhejiang University School of Medicine, Hangzhou, China.
AD  - Orthopaedic Research Institute, Zhejiang University, Hangzhou, China.
AD  - Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang 
      Province, Hangzhou, China.
AD  - The Second Clinical Medical College of Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Ye, Zhaoming
AU  - Ye Z
AD  - Orthopaedic Oncology Services, Department of Orthopaedics, The Second Affiliated 
      Hospital of Zhejiang University School of Medicine, Hangzhou, China.
AD  - Orthopaedic Research Institute, Zhejiang University, Hangzhou, China.
AD  - Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang 
      Province, Hangzhou, China.
AD  - The Second Clinical Medical College of Zhejiang Chinese Medical University, 
      Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20230810
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC10447977
OTO - NOTNLM
OT  - bone morphogenetic protein-2
OT  - controllable release
OT  - hydrogel
OT  - large bone defects
OT  - mineral coating
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/28 06:42
MHDA- 2023/08/28 06:43
PMCR- 2023/01/01
CRDT- 2023/08/28 04:30
PHST- 2023/05/05 00:00 [received]
PHST- 2023/07/27 00:00 [accepted]
PHST- 2023/08/28 06:43 [medline]
PHST- 2023/08/28 06:42 [pubmed]
PHST- 2023/08/28 04:30 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 1217335 [pii]
AID - 10.3389/fbioe.2023.1217335 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2023 Aug 10;11:1217335. doi: 10.3389/fbioe.2023.1217335. 
      eCollection 2023.